Clinical Trial Detail

NCT ID NCT01994590
Title Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Recruitment Terminated
Gender male
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center|Novartis
Indications

prostate cancer

Therapies

Dovitinib

Age Groups: adult

No variant requirements are available.